January 31, 2018
Boehringer Ingelheim appoints new CEO
Boehringer Ingelheim has appointed new CEO Wednesday, who will replace Paul Fonteyne, as he will retire after 15 years, on December…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Boehringer Ingelheim
January 16, 2018
FDA broadens Boehringer Ingelheim’s afatinib indication to previously untreated, metastatic NSCLC
Boehringer Ingelheim Pharmaceuticals has gotten an approval from the FDA, for a broadened indication of its afatinib for patients with…
January 3, 2018
Boehringer Ingelheim doubles funding to 250 M€ for its corporate venture fund
Boehringer Ingelheim today announced an increase in funding for its corporate venture fund, known as the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million.
December 20, 2017
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
Boehringer Ingelheim today announced a collaborative agreement with Roche, focusing on the discovery and development of orally available novel Locked…
November 14, 2017
Hikma buys 6 Boehringer’s products
Hikma Pharmaceuticals has acquired six products from Boehringer Ingelheim GmbH (Boehringer Ingelheim).
July 11, 2017
Boehringer Ingelheim reports results from life-threatening bleeding drug study
Boehringer Ingelheim has reported that final results from RE-VERSE AD study showed that idarucizumab, marketed in the U.S. as Praxbind, was able to immediately reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate) in patients in emergency situations.
June 13, 2017
BI, Eli Lilly to test Jardiance for more tratments
Boehringer Ingelheim (BI) and Eli Lilly are preparing to investigate Jardiance (empagliflozin) tablets for the treatment of people with chronic kidney disease.
May 23, 2017
Boehringer Ingelheim’s asthma drug test shows good results
Boehringer Ingelheim has reported new analyses that provide further evidence that adding SPIRIVA RESPIMAT improved breathing across diverse patient populations who experience uncontrolled asthma symptoms despite the use of another daily maintenance therapy in the Phase III clinical development program.
February 22, 2017
Verona kicks off phase two for its COPD candidate RPL544 as add-on to Spiriva
Verona Pharma has made an important step in the phase two clinical trial for its candidate RPL554, used for chronic obstructive pulmonary disease (COPD). Namely, the first patient has been dosed testing RPL544 as an add-on therapy to tiotropium, Spiriva.
February 9, 2017
Pulmonary drug delivery devices market to reach $43.05 billion by 2024
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.